>R&D>Research Alliances

Research Alliances

In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

Research Alliances with overseas research organizations and companies

As of September 30, 2014

PartnerCountryResearch subjectSchedule
XOMA Ltd. U.S. Joint research on discovery, development and production technologies of monoclonal antibody 2006/11-
Seattle Genetics U.S. Research collaboration on Antibody-Drug Conjugate 2009/3-
University College London U.K. Research collaboration on development of novel cancer treatment 2010/3-2014/3
Sage Bionetworks U.S. Research collaboration on discovering effective therapeutic targets for Central Nervous System (CNS) disease 2010/11-2015/6
Florida Hospital, Sanford-Burnham Medical Research Institute U.S. Research collaboration to target obesity 2010/12-
Zinfandel Pharmaceuticals U.S. Licensing Agreement for Alzheimer's Disease Biomarker TOMM40 for the risk of Alzheimer's disease 2010/12-
Structural Genomics Consortium Canada Participation in consortium to advance basic research on selected drug targets based on three-dimensional structures of human proteins 2011/7-2015/6
* Takeda joined 2012/4
BC Cancer Agency Canada Research collaboration to explore new drug targets based on gene analysis 2012/8-2015/7
Advinus Therapeutics India Discovery collaboration focused on novel targets for marjor therapeutic areas, including Inflammation, CNS, and Metabolic diseases 2012/10-2015/9
Resolve Therapeutics U.S. Collaboration to develop compounds for the treatment of Systemic Lupus Erythematosus (SLE) 2013/2-
Tri-Institutional Therapeutics Discovery Institute U.S. Collaboration of academic institutions and industry to more effectively develop innovative treatments and therapies 2013/10-2016/9
Trianni, Inc. U.S. Agreement for use of Trianni’s next generation transgenic mouse platform for the generation of human monoclonal antibodies against disease targets in all therapeutic areas 2014/3-
MacroGenics U.S. Collaboration to research and develop product candidates that will be directed against jointly selected pairs of molecular targets and using MacroGenics’ Dual-Affinity Re-Targeting (DART®) proprietary platform. 2014/9-

Research Alliances with domestic research organizations and companies

PartnersResearch subjectSchedule
Kirin Brewery Company Ltd. (Now Kyowa Hakko Kirin Ltd.) Licensing-in of the human antibody technology 2003/7-
Kyoto University Research collaboration for basic and clinical research project of discovering treatments for obesity and schizophrenia based on CNS control 2011/1-2016/3
Osaka University Joint research on development of platform for practical application and commercialization of nano-particle vaccines 2012/2-2015/1